Inhaled treprostinil for Raynaud's attacks in scleroderma
Part of Heart & circulation, Skin clinical trials.
This study tests an inhaled medication to reduce the frequency of Raynaud's attacks in people with scleroderma. It may help improve blood flow and reduce pain or color changes in fingers and toes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of systemic sclerosis (scleroderma).
- You must have Raynaud's phenomenon, with at least 12 symptomatic attacks over 4 or more separate days.
- You cannot have more than 2 digital ulcers at screening, or any new ulcers, gangrene, or recent infections.
- You must not have pulmonary hypertension or severe lung disease, and you cannot require supplemental oxygen.
- You must not have used certain blood pressure or prostacyclin medications within the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
This study tests whether changing from the oral medicine selexipag to an inhaled treatment called treprostinil (LIQ861) can improve symptoms or be better tolerated in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. If you are currently taking selexipag but it isn't working well enough or causes side effects, this switch might be a good option for you.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
Hear when a new Raynaud's Phenomenon Secondary to Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.